Abingworth

What is Abingworth?

Abingworth is an international investment firm focused on the life sciences and healthcare sectors. Founded in 1973, they have a long history of backing developing life science and medical enterprises. Abingworth provides funding across all stages of company development - from early-stage ventures to growth equity and public companies.

Their investments range from $15 to $30 million, aiming for a sweet spot of approximately $22.5 million. Abingworth specializes in diverse financial activities such as seed and startup investments, early stage, expansion, later stage, restructuring, consolidation, PIPE (Private Investment in Public Equity), going private transactions, and Series A and B funding rounds.

With an expertise in equity investments, they manage assets of around $1.8 billion and operate offices in key locations including London, Boston, and Menlo Park, ensuring a strong transatlantic presence. Their portfolio extends across the United States and Europe, with a particular focus on the U.K., Belgium, Denmark, France, Germany, Holland, and Sweden. The investment team is known to use innovative approaches like VIPEs (Venture Investments in Public Equities) and Clinical Co-Development to support their portfolio companies.

Abingworth maintains a robust network and is actively involved in the discovery and development of new therapies, continuously seeking out new advancements and investment opportunities in the life sciences and healthcare landscape.

What they say:

We are an international investment group that partners with entrepreneurs in the industry.

What we look for: We invest in biotech, diagnostics, life sciences, and medical devices.